Common Stock, $0.001 par value
- Symbol
- MNOV
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01 · 8-K
Medicinova Inc
MNOVNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026, MediciNova, Inc. (the “Company”) amended its Lease (the “Lease”), dated July 20, 2021, between the Company and the Irvine Company LLC pursuant to a First Amendment to the Lease, dated as of September 23, 2026 (the “Amendment”), by and between the Company and Newport Gateway Office LLC.…
Company context
We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (“U.S.”) market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (“MS”), amyotrophic lateral sclerosis (“ALS”), chemotherapy-induced peripheral neuropathy (“CIPN”), degenerative cervical myelopathy (“DCM”), glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence), and prevention of acute respiratory distress syndrome (“ARDS”), and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (“NAFLD”), and hypertriglycedemia.
Current securities
Recent company filings
- Termination of a Material Definitive AgreementSep 2, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 19, 2026
- 10-Q filingAug 13, 2026
- Submission of Matters to a Vote of Security HoldersJun 24, 2026
- 10-Q filingMay 14, 2026
Registered securities in this filing
MEDICINOVA INC · 8-K · Filed 2026-09-28
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On September 23, 2026, MediciNova, Inc. (the “Company”) amended its Lease (the “Lease”), dated July 20, 2021, between the Company and the Irvine Company LLC pursuant to a First Amendment to the Lease, dated as of September 23, 2026 (the “Amendment”), by and between the Company and Newport Gateway Office LLC. Pursuant to the Amendment, among other things, the parties extended the end date of the Lease from January 31, 2027 to April 30, 2030, unless sooner terminated in accordance with the terms of the Lease, and agreed to certain rent increases taking effect on February 1, 2027.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is expected to be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.